이화여자대학교 의료원 logo
항생제
Daptomycin

Daptomycin

제한된

N/A
N/A

Spectrum Of Activity

General Spectrum of Activity
​

General Information

  • Bacteremia due to Staphylococcus aureus.
  • Infection of skin and/or subcutaneous tissue, complicated.
  • Methicillin-resistant Staphylococcus aureus infection.

Monitor serum CPK; weekly during use in all patients and more frequently in patients with recent prior or concomitant HMG-CoA reductase inhibitor therapy, renal insufficiency, or elevations in CPK.

Monitor renal function.

Monitor muscle pain or weakness, especially in the distal extremities.

Monitor signs and symptoms of peripheral neuropathy during use.

Repeat blood cultures and diagnostic evaluation for infectious foci; in patients with persistent or relapsing Staph. aurues bacteremia, endocarditis, or poor clinical response.

Common

  • Fever
  • Rash
  • Diarrhea
  • Vomiting
  • Headache
  • Abdominal pain
  • Hypertension
  • Pruritus
  • Insomnia
  • Dyspnea

Serious

  • Renal failure
  • Increased creatine kinase level
  • Rhabdomyolysis
  • Pulmonary eosinophilia

HMG-CoA reductase inhibitors- increased risk of myopathy or rhabdomyolysis

Antimicrobial class: Lipopeptide

Pregnancy category: B

Average serum half life: 8-9 hours

CSF penetration: Poor

Lung penetration: Poor

Urine penetration: Therapeutic

Precautions:

  • Decreased efficacy was reported for patients with moderate renal impairment (CrCl <50 mL/min).
  • Discontinue if anaphylaxis and hypersensitivity reactions are suspected.
  • Avoid use in patients younger than 12 months due to potential risk to muscular, neuromuscular, or peripheral/central nervous systems.